Your shopping cart is currently empty

Synonyms: Methyl 8-[2-[(2-pentylcyclopropyl)methyl]cyclopropyl]octanoate, Methyl 8-(2-((2-pentylcyclopropyl)methyl)cyclopropyl)octanoate, DCPLA methyl ester, 2-[(2-Pentylcyclopropyl)methyl]cyclopropaneoctanoic acid methyl ester


| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $59 | In Stock | In Stock | |
| 5 mg | $135 | In Stock | In Stock | |
| 10 mg | $190 | In Stock | In Stock | |
| 25 mg | $389 | - | In Stock | |
| 50 mg | $636 | - | In Stock | |
| 100 mg | $858 | - | In Stock | |
| 200 mg | $1,170 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $148 | - | In Stock |
| Description | DCPLA-ME (2-[(2-Pentylcyclopropyl)methyl]cyclopropaneoctanoic acid methyl ester) is the methyl ester form of DCPLA. DCPLA-ME is a highly selective PKCε activator with antioxidant and anti-inflammatory activities. DCPLA-ME can be used in research on neurodegenerative diseases. |
| In vivo | Methods: 16-month-old 3×Tg-AD mice (carrying APP/PS1/Tau triple mutations) and wild-type control mice were used. Multiple microinfarcts were induced in the brain by injecting approximately 2000 fluorescent microspheres (20 μm) into the right common carotid artery. Approximately 18 hours post-surgery, intraperitoneal injections of DCPLA-ME (3 mg/kg body weight, dissolved in sterile saline) were initiated at a frequency of three times weekly for two weeks. Control mice received an equal volume of solvent. Results: DCPLA-ME treatment significantly improved spatial memory deficits in 3×Tg+MI mice, reduced oxidative stress and apoptosis, alleviated persistent hypoxia, and protected microvascular structure, synapses, and myelin sheaths. [1] |
| Synonyms | Methyl 8-[2-[(2-pentylcyclopropyl)methyl]cyclopropyl]octanoate, Methyl 8-(2-((2-pentylcyclopropyl)methyl)cyclopropyl)octanoate, DCPLA methyl ester, 2-[(2-Pentylcyclopropyl)methyl]cyclopropaneoctanoic acid methyl ester |
| Molecular Weight | 322.53 |
| Formula | C21H38O2 |
| Cas No. | 56687-67-3 |
| Smiles | CCCCCC1CC1CC1CC1CCCCCCCC(=O)OC |
| Relative Density. | 0.938 g/cm3 (Predicted) |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (310.05 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (10.23 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.